Evaluation of the clinical efficacy, safety, and permeability in pulmonary epithelial lining fluid of contezolid, a novel oxazolidinone drug, in adult patients with pneumonia
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01033-25 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Hailan Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Oxazolidinones, Pneumonia, Bacterial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Contezolid is a novel oxazolidinone antibiotic for the treatment of gram-positive bacteria, which are one of the most common pathogens of pneumonia. We conducted a prospective, single-center, open-label study to evaluate the clinical and microbiological efficacy, safety profile, and pulmonary epithelial lining fluid (ELF) penetration characteristics of contezolid in adult pneumonia patients. Sparse blood samples and bronchoalveolar lavage fluid samples were collected from patients after multiple oral doses of 800 mg of contezolid twice a day. Pharmacokinetic parameters were calculated by developing population pharmacokinetic (PopPK) modeling, and probability of target attainment was evaluated by Monte Carlo simulations. The study enrolled 15 patients (mean age 55 years) with primarily community-acquired pneumonia. Contezolid achieved a clinical cure rate of 80.0% and a bacterial clearance rate of 71.4%. Oral contezolid was well tolerated, and no drug-related adverse effects were observed in any of the subjects. The mean area under the concentration-time curve (AUC ₀–₁₂,ss ) was estimated by the PopPK model to be 33.06 mg·h/L in ELF and 71.95 mg·h/L in plasma. Assuming a plasma protein binding rate of 90% based on literature data, the ELF-to-free plasma AUC 0–12,ss ratio was 4.50. When the minimum inhibitory concentration was ≤4 mg/L, 800 mg of contezolid q12h could achieve the optimal therapeutic target in the plasma of patients with pneumonia. This study demonstrates that contezolid achieved excellent pulmonary penetration in adult patients with pneumonia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
- Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People's Republic of China, Shanghai, People's Republic of China.
- National Clinical Research Center for Geriatric Diseases, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
- Joint Laboratory of Hospital & Enterprise for Pathogen Diagnosis of Drug-resistant Bacterial Infections and lnnovative Drug R&D, Shanghai, People's Republic of China.
- Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
- Department of Respiratory and Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
ORCID-Profile: Zixuan Cheng, Fengming Ding, Yuancheng Chen, Tao Chen, Jing Zhang, Jing Zhang
Zitieren
APA
Wu, H., Cheng, Z., Ding, F., Hua, J., Wang, H., Meng, X., Cao, Y., Chen, Y., Chen, Y., Guo, B., Chen, T., Zhang, J., & Zhang, J. (2026). Evaluation of the clinical efficacy, safety, and permeability in pulmonary epithelial lining fluid of contezolid, a novel oxazolidinone drug, in adult patients with pneumonia. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01033-25
Vancouver
Wu H, Cheng Z, Ding F, Hua J, Wang H, Meng X, et al. Evaluation of the clinical efficacy, safety, and permeability in pulmonary epithelial lining fluid of contezolid, a novel oxazolidinone drug, in adult patients with pneumonia. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01033-25
BibTeX
@article{Wu2026,
author = {Wu, Hailan and Cheng, Zixuan and Ding, Fengming and Hua, Jianlan and Wang, Hailin and Meng, Xiannan and Cao, Yanmei and Chen, Yuancheng and Chen, Yan and Guo, Beining and Chen, Tao and Zhang, Jing and Zhang, Jing},
title = {Evaluation of the clinical efficacy, safety, and permeability in pulmonary epithelial lining fluid of contezolid, a novel oxazolidinone drug, in adult patients with pneumonia},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01033-25}
}
EUVIMED